caa a22 4500 465737684 CHVBK 20180323111759.0 cr unu---uuuuu 170327e19901001xx s 000 0 eng 10.1007/BF02245921 doi (NATIONALLICENCE)springer-10.1007/BF02245921 Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice [Elektronische Daten] [Joanne Sweeney, Eric Bachman, Joseph Coyle] The effects of galanthamine, a long-acting acetylcholinesterase inhibitor, on passive avoidance and a modified Morris swim task were studied in mice. Lesions of the nucleus basalis magnocellularis (nBM) produced significant decreases in cortical choline acetyltransferase (ChAT) activity and profound deficits on the 24-h retention of a passive avoidance response and the reversal phase of the swim task. Galanthamine, administered 4 h before testing, improved performance of the two tasks in a dose-dependent fashion. In both tasks, galanthamine produced a U-shaped dose-response curve: the optimal dose was 3.0 mg/kg, IP on passive avoidance and 2.0 mg/kg on the swim task. The improvements in performance were not due to differences in motor activity or sensitivity to electric footshock. Behavioral tolerance did not occur from repeated doses of galanthamine; in fact, prior doses of galanthamine appeared to have a priming effect on later performance. In contrast to the effects in nBM-lesioned mice, galanthamine impaired performance of control mice on both tasks. Several characteristics of galanthamine suggest that it may be effective in treating the central cholinergic deficits in Alzheimer's disease: 1) its ability to attentuate cognitive deficits in nBM-lesioned mice, 2) its relatively long half-life, and 3) its lack of tolerance effects in mice during 2 weeks of repeated dosing. Springer-Verlag, 1990 Long-acting acetylcholinesterase inhibitor nationallicence Galanthamine nationallicence nBM lesion nationallicence Mice nationallicence Memory nationallicence Passive avoidance nationallicence Morris swim task nationallicence Sweeney Joanne Department of Environmental Health Sciences, Toxicological Sciences Division, The Johns Hopkins University School of Public Health, 21205, Baltimore, MD, USA aut Bachman Eric Departments of Psychiatry, Neuroscience and Pharmacology, The Johns Hopkins University School of Medicine, 21205, Baltimore, MD, USA aut Coyle Joseph Departments of Psychiatry, Neuroscience and Pharmacology, The Johns Hopkins University School of Medicine, 21205, Baltimore, MD, USA aut Psychopharmacology Springer-Verlag 102/2(1990-10-01), 191-200 0033-3158 102:2<191 1990 102 213 https://doi.org/10.1007/BF02245921 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245921 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sweeney Joanne Department of Environmental Health Sciences, Toxicological Sciences Division, The Johns Hopkins University School of Public Health, 21205, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Bachman Eric Departments of Psychiatry, Neuroscience and Pharmacology, The Johns Hopkins University School of Medicine, 21205, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Coyle Joseph Departments of Psychiatry, Neuroscience and Pharmacology, The Johns Hopkins University School of Medicine, 21205, Baltimore, MD, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 102/2(1990-10-01), 191-200 0033-3158 102:2<191 1990 102 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer